LIVOSTIN
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Nov 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVOSTIN is an ophthalmic suspension approved in 1993 for allergic conjunctivitis and related eye conditions. The exact mechanism of action is not specified in available data, but it is formulated as eye drops for topical ocular administration. It is a small-molecule therapeutic in the mature phase of its lifecycle.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a defensive commercial posture and likely focus on lifecycle extension or managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIVOSTIN presents limited near-term career growth opportunities given its LOE-approaching status and zero linked job openings. Positions on this product team are likely defensive, focused on maximizing remaining exclusivity and managing competitive or generic transition rather than building new capabilities.
Brand ManagerSenior Manager, Market Access
Worked on LIVOSTIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.